Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Northwest Biotherapeutics (NWBO) just unveiled an announcement.
Pat Sarma has been appointed as a Class II director and member of the Audit, Compensation, and Conflicts Committees, effective March 18, 2024. His appointment came with no prior arrangements and is free from any related-party transactions requiring disclosure. As an independent director, Sarma will receive the same compensation as other non-employee directors of the company.
For detailed information about NWBO stock, go to TipRanks’ Stock Analysis page.